AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- US stock futures dip as oil breaches $100 mark for the first time since mid-year
- Oil nears $100 as fresh Middle East strikes raise supply risks
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Abbvie (ABBV) PT Raised to $180 at Goldman Sachs
February 5, 2024 5:58 AM ESTGoldman Sachs analyst Chris Shibutani raised the price target on Abbvie (NYSE: ABBV) to $180.00 (from $173.00) while maintaining a Buy rating.
The analyst comments "4Q23 results and management's commentary on the FY24 and longer-term outlook strengthen our confidence in the potential for ABBV shares to continue to outperform. Across the company's Immunology... More
AbbVie (ABBV) tops Q4 earnings, revenue consensus estimate
February 2, 2024 8:37 AM ESTAbbVie (NYSE: ABBV) shares edged around 1% higher early Friday after the company reported earnings before the open, topping fourth-quarter profit and revenue expectations.
The American pharmaceutical company reported fourth-quarter adjusted earnings of $2.79 per share, $0.02 better than the analyst estimate of $2.77. Meanwhile, revenue... More
AbbVie (ABBV) Tops Q4 EPS by 2c, Beats on Revenue; Offers FY24 EPS Guidance
February 2, 2024 7:37 AM EST(Updated - February 2, 2024 7:40 AM EST)
AbbVie (NYSE: ABBV) reported Q4 EPS of $2.79, $0.02 better than the analyst estimate of $2.77. Revenue for the quarter came in at $14.3 billion versus the consensus estimate of $14.01 billion.
GUIDANCE:
AbbVie sees FY2024 EPS of... More
